Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Keyphrases

• Atopic Dermatitis 100%
• Placebo-controlled 100%
• Phase II Trial 100%
• Randomized Double-blind 100%
• Dupilumab 100%
• Topical Corticosteroids 36%
• Placebo 27%
• Placebo Groups 27%
• Investigator's Global Assessment 27%
• Moderate-to-severe Atopic Dermatitis 27%
• Older Adults 18%
• Adverse Events 18%
• Older children 18%
• Assessment Score 18%
• Low Potencies 18%
• Systemic Treatment 9%
• Eczema 9%
• Europe 9%
• North America 9%
• Inflammatory Conditions 9%
• Severity Index 9%
• Consensus Criteria 9%
• Lack of Response 9%
• Safety Profile 9%
• Treatment Discontinuation 9%
• Treatment Allocation 9%
• Safety Analysis 9%
• Topical Therapy 9%
• Area Index 9%
• Response System 9%
• Conjunctivitis 9%
• Hospital Clinic 9%
• Co-primary Endpoints 9%
• Acceptable Safety 9%
• Background Current 9%
• Hydrocortisone Acetate 9%
• American Academy of Dermatology 9%
• Clear or Almost Clear Skin 9%
• Interactive Web Response 9%
• Patient Allocation 9%

Medicine and Dentistry

• Atopic Dermatitis 100%
• Placebo 100%
• Dupilumab 100%
• Topical Corticosteroid 36%
• Adverse Event 18%
• Prevalence 9%
• Systemic Therapy 9%
• Serositis 9%
• Topical Treatment 9%
• Physical Disease by Body Function 9%
• Conjunctivitis 9%
• Eczema 9%
• Hydrocortisone Acetate 9%
• Dermatology 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Atopic Dermatitis 100%
• Dupilumab 100%
• Topical Corticosteroid 36%
• Adverse Event 18%
• Systemic Treatment 9%
• Prevalence 9%
• Physical Disease by Body Function 9%
• Eczema 9%
• Hydrocortisone Acetate 9%
• Inflammation 9%